Novavax [NVAX] vs Vericel [VCEL] Detailed Stock Comparison
Novavax
NASDAQ
Loading...
Vericel
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Novavax wins in 12 metrics, Vericel wins in 6 metrics, with 0 ties. Novavax appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Novavax | Vericel | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 4.04 | 255.21 | Novavax |
| Price-to-Book Ratio | 38.62 | 5.87 | Vericel |
| Debt-to-Equity Ratio | 607.28 | 32.74 | Vericel |
| PEG Ratio | -0.10 | 74.44 | Novavax |
| EV/EBITDA | 2.85 | 190.23 | Novavax |
| Profit Margin (TTM) | 39.20% | 2.85% | Novavax |
| Operating Margin (TTM) | 44.17% | -3.21% | Novavax |
| EBITDA Margin (TTM) | 44.17% | N/A | N/A |
| Return on Equity | 30.06% | 2.59% | Novavax |
| Return on Assets (TTM) | 14.52% | 0.18% | Novavax |
| Free Cash Flow (TTM) | $-101.90M | $-5.81M | Vericel |
| 1-Year Return | -34.61% | -24.87% | Vericel |
| Price-to-Sales Ratio (TTM) | 1.35 | 7.24 | Novavax |
| Enterprise Value | $1.16B | $1.81B | Vericel |
| EV/Revenue Ratio | 1.08 | 7.26 | Novavax |
| Gross Profit Margin (TTM) | 93.59% | 73.71% | Novavax |
| Revenue per Share (TTM) | $7 | $5 | Novavax |
| Earnings per Share (Diluted) | $2.22 | $0.14 | Novavax |
| Beta (Stock Volatility) | 2.50 | 1.27 | Vericel |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Novavax vs Vericel Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Novavax | 2.75% | -18.16% | 8.59% | 7.54% | 5.80% | -8.52% |
| Vericel | 4.49% | 2.07% | -2.50% | -10.51% | -29.24% | -32.81% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Novavax | -34.61% | -77.73% | -92.72% | -96.63% | -81.15% | -70.75% |
| Vericel | -24.87% | 36.79% | 126.21% | 1,068.14% | 32.25% | -91.70% |
Performance & Financial Health Analysis: Novavax vs Vericel
| Metric | NVAX | VCEL |
|---|---|---|
| Market Information | ||
| Market Cap | $1.46B | $1.80B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 7,807,163 | 456,322 |
| 90 Day Avg. Volume | 6,635,331 | 589,887 |
| Last Close | $7.84 | $37.03 |
| 52 Week Range | $5.01 - $15.22 | $33.09 - $63.00 |
| % from 52W High | -48.49% | -41.22% |
| All-Time High | $331.68 (Feb 08, 2021) | $1,590.00 (Sep 22, 1997) |
| % from All-Time High | -97.64% | -97.67% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.42% | 0.20% |
| Quarterly Earnings Growth | -0.34% | 0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.39% | 0.03% |
| Operating Margin (TTM) | 0.44% | -0.03% |
| Return on Equity (TTM) | 0.30% | 0.03% |
| Debt to Equity (MRQ) | 607.28 | 32.74 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.23 | $6.08 |
| Cash per Share (MRQ) | $3.77 | $2.32 |
| Operating Cash Flow (TTM) | $-630,940,992 | $47.24M |
| Levered Free Cash Flow (TTM) | $-627,235,008 | $-5,594,625 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Novavax vs Vericel
| Metric | NVAX | VCEL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 4.04 | 255.21 |
| Forward P/E | -56.00 | 74.44 |
| PEG Ratio | -0.10 | 74.44 |
| Price to Sales (TTM) | 1.35 | 7.24 |
| Price to Book (MRQ) | 38.62 | 5.87 |
| Market Capitalization | ||
| Market Capitalization | $1.46B | $1.80B |
| Enterprise Value | $1.16B | $1.81B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.08 | 7.26 |
| Enterprise to EBITDA | 2.85 | 190.23 |
| Risk & Other Metrics | ||
| Beta | 2.50 | 1.27 |
| Book Value per Share (MRQ) | $0.23 | $6.08 |
Financial Statements Comparison: Novavax vs Vericel
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NVAX | VCEL |
|---|---|---|
| Revenue/Sales | $626.33M | $52.60M |
| Cost of Goods Sold | $14.12M | $16.33M |
| Gross Profit | $612.22M | $36.27M |
| Research & Development | $88.94M | $7.26M |
| Operating Income (EBIT) | $515.51M | $-12.79M |
| EBITDA | $533.91M | $-8.41M |
| Pre-Tax Income | $519.85M | $-11.25M |
| Income Tax | $1.20M | N/A |
| Net Income (Profit) | $518.65M | $-11.25M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NVAX | VCEL |
|---|---|---|
| Cash & Equivalents | $263.34M | $73.49M |
| Total Current Assets | $868.03M | $197.64M |
| Total Current Liabilities | $422.17M | $39.45M |
| Long-Term Debt | $223.18M | $87.80M |
| Total Shareholders Equity | $-75.64M | $295.49M |
| Retained Earnings | $-4.49B | $-404.06M |
| Property, Plant & Equipment | $291.03M | $68.72M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NVAX | VCEL |
|---|---|---|
| Operating Cash Flow | $-185.78M | $12.44M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | $-187.10M | $-7.61M |
| Debt Repayment | $-2.20M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NVAX | VCEL |
|---|---|---|
| Shares Short | 42.31M | 5.56M |
| Short Ratio | 8.53 | 9.32 |
| Short % of Float | 0.26% | 0.14% |
| Average Daily Volume (10 Day) | 7,807,163 | 456,322 |
| Average Daily Volume (90 Day) | 6,635,331 | 589,887 |
| Shares Outstanding | 160.42M | 49.63M |
| Float Shares | 136.72M | 49.90M |
| % Held by Insiders | 0.09% | 0.01% |
| % Held by Institutions | 0.59% | 1.11% |
Dividend Analysis & Yield Comparison: Novavax vs Vericel
| Metric | NVAX | VCEL |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |